To explore the impact of ILT4 blockade on the efficacy of PD-L1 inhibitor in TKI-resistant NSCLC, we first established gefitinib-resistant PC9 (PC9-GR) cells by long-term stimulation of parental PC9 cells with low-dose gefitinib. The gene discussed is CD274; the disease is non-small cell lung carcinoma.